Christopher Downs net worth and biography

Christopher Downs Biography and Net Worth

Mr. Downs is the Chief Financial Officer of CNS Pharmaceuticals, Inc. Mr. Downs has served in senior finance executive and public company director positions for over 20 years, primarily in the healthcare industry. Mr. Downs also serves as a Director and Audit Committee Chairman of Esports Technologies, Inc. Prior to his current role, he served as Executive Vice President and Chief Financial Officer for InfuSystem Holdings, Inc., a supplier of infusion services to oncologists in the United States and worked at several boutique M&A advisory firms in Analyst, Associate and Vice President roles. In addition to his M&A experience, he has formal credit training from Citigroup and has worked on a both debt and equity capital markets offerings into the public and private markets. Mr. Downs is a graduate of the United States Military Academy at West Point where he earned his Bachelor of Science. Mr. Downs earned his MBA at Columbia Business School and his Master of Science in Accounting at the University of Houston-Clear Lake. Mr. Downs is a Certified Public Accountant.

What is Christopher Downs' net worth?: The estimated net worth of Christopher Downs is at least $91.43 as of August 22nd, 2023. Mr. Downs owns 735 shares of CNS Pharmaceuticals stock worth more than $91 as of November 23rd. This net worth approximation does not reflect any other investments that Mr. Downs may own. Additionally, Mr. Downs receives a salary of $382,160.00 as CFO at CNS Pharmaceuticals. Learn More about Christopher Downs' net worth.
How old is Christopher Downs?: Mr. Downs is currently 45 years old. There are 3 older executives and no younger executives at CNS Pharmaceuticals. The oldest executive at CNS Pharmaceuticals is Dr. Donald H. Picker Ph.D., Chief Science Officer, who is 78 years old. Learn More on Christopher Downs' age.
What is Christopher Downs' salary?: As the CFO of CNS Pharmaceuticals, Inc., Mr. Downs earns $382,160.00 per year. The highest earning executive at CNS Pharmaceuticals is Mr. John Michael Climaco Esq., J.D., CEO, President & Director, who commands a salary of $525,000.00 per year. Learn More on Christopher Downs' salary.
How do I contact Christopher Downs?: The corporate mailing address for Mr. Downs and other CNS Pharmaceuticals executives is 2100 WEST LOOP SOUTH SUITE 900, HOUSTON TX, 77027. CNS Pharmaceuticals can also be reached via phone at 800-946-9185 and via email at [email protected]. Learn More on Christopher Downs' contact information.
Has Christopher Downs been buying or selling shares of CNS Pharmaceuticals?: Christopher Downs has not been actively trading shares of CNS Pharmaceuticals in the last ninety days. Most recently, on Tuesday, August 22nd, Christopher Downs bought 540 shares of CNS Pharmaceuticals stock. The stock was acquired at an average cost of $63.50 per share, with a total value of $34,290.00. Following the completion of the transaction, the chief financial officer now directly owns 735 shares of the company's stock, valued at $46,672.50. Learn More on Christopher Downs' trading history.

Christopher Downs Insider Trading History at CNS Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/22/2023	Buy	540	$63.50	$34,290.00	735
4/17/2023	Buy	62	$160.00	$9,920.00	185
12/6/2021	Buy	100	$47.00	$4,700.00
11/19/2021	Buy	90	$57.50	$5,175.00
8/24/2020	Buy	2,840	$102.00	$289,680.00	2,840

Christopher Downs Buying and Selling Activity at CNS Pharmaceuticals

CNS Pharmaceuticals Company Overview

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Today's Range

Now: $0.12

$0.11

$0.13

50 Day Range

MA: $0.13

$0.11

$0.16

2 Week Range

Now: $0.12

$0.10

$121.00

Volume

9,849,799 shs

Average Volume

11,285,534 shs

Market Capitalization

$7.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.58

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>